Tag: pharmaceuticals
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and...
ViaDerma, Inc. Provides Preliminary Revenue Estimates and Highlights for its Record...
LOS ANGELES, April 08, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), is pleased to provide an update of...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery,...
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare...
RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan...
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in...
Flow Chemistry Market Size To Reach USD 3.27 Billion in 2028;...
New York, March 29, 2021 (GLOBE NEWSWIRE) -- Increasing adoption of flow chemistry in pharmaceutical, chemicals, and petrochemicals industries is key...
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results...
Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second...
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies...
EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial...
Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing...
-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- --...
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab...
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the...